MedPath

AST-120 Used to Treat Mild Hepatic Encephalopathy

Phase 2
Completed
Conditions
Mild Hepatic Encephalopathy
Interventions
Registration Number
NCT00867698
Lead Sponsor
Ocera Therapeutics
Brief Summary

The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
148
Inclusion Criteria
  1. Confirmed cirrhosis of any cause
  2. Abnormal RBANS global summary score
  3. Grade 0 or 1 hepatic encephalopathy by West-Haven Scale
  4. MELD score < or = 25
  5. Females must be postmenopausal, surgically incapable of bearing children or practicing a reliable method of birth control
Exclusion Criteria
  1. Previous participation in any trial involving AST-120
  2. History of TIPS or surgically created portocaval shunt
  3. Treatment for overt HE within the past 3 months
  4. Use of lactulose, rifaximin, neomycin or other antibiotics in the past 7 days
  5. Active alcohol abuse
  6. Psychosis or organic brain syndromes due to alcohol or other causes
  7. Use of interferon and sedating or cognition-altering drugs
  8. Undergoing chemotherapy or radiotherapy for the treatment of cancer
  9. Active GI bleeding within the past 3 months
  10. Presence of an active infection
  11. Presence of signs and symptoms of severe dehydration
  12. Other major physical or major psychiatric illness within the past 6 months
  13. Pregnant, breast feeding, or planning to become pregnant during the study
  14. Using hormonal contraception as the only method of birth control

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AST-120 (6g)AST-1202 grams TID
Placebo AAST-1202 grams TID
AST-120 (12g)AST-1204 grams TID
Placebo BAST-1204 grams TID
Primary Outcome Measures
NameTimeMethod
Neurocognitive improvement, defined as the change in the global summary score of the RBANS at Week 8 compared to Baseline.8 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (37)

Beth Israel Deaconnes Medical Center, Harvard Medical School

🇺🇸

Boston, Massachusetts, United States

Albert Einstein Medical Center, Division of Hepatology

🇺🇸

Philadelphia, Pennsylvania, United States

UT Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

New York Medical College

🇺🇸

Valhalla, New York, United States

Case Western Reserve / MetroHealth Medical Center

🇺🇸

Cleveland, Ohio, United States

Mayo Clinic Arizona

🇺🇸

Phoenix, Arizona, United States

Scripps Clinic

🇺🇸

San Diego, California, United States

University of Utah Health Sciences Center

🇺🇸

Salt Lake City, Utah, United States

California Pacific Medical Center

🇺🇸

San Francisco, California, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Northwestern University, Feinberg School of Medicine

🇺🇸

Chicago, Illinois, United States

University of Cincinatti

🇺🇸

Cincinatti, Ohio, United States

University of Florida College of Medicine

🇺🇸

Gainesville, Florida, United States

UCSF - Fresno Community Regional Medical Center

🇺🇸

Fresno, California, United States

Baylor University Medical Center

🇺🇸

Dallas, Texas, United States

UCSD Medical Center

🇺🇸

San Diego, California, United States

Yale University School of Medicine

🇺🇸

New Haven, Connecticut, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

VA Medical Center / University of Iowa Hospital and Clinics

🇺🇸

Iowa City, Iowa, United States

Tulane University Health Sciences Center

🇺🇸

New Orleans, Louisiana, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Weill Medical College of Cornell

🇺🇸

New York, New York, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Temple University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Medical University of Southern Carolina

🇺🇸

Charleston, South Carolina, United States

Advanced Liver Therapies, St. Luke's Episcopal Hospital/Baylor College of Medicine

🇺🇸

Houston, Texas, United States

Permian Research Foundation

🇺🇸

Odessa, Texas, United States

McGuire DVAMC

🇺🇸

Richmond, Virginia, United States

University of Rochester Medical Center

🇺🇸

Rochester, New York, United States

Dartmouth Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

University of Miami, Division of Hepatology / Center for Liver Disease

🇺🇸

Miami, Florida, United States

Washington Hospital Center

🇺🇸

Washington, District of Columbia, United States

University of Massachusetts Memorial Medical Center

🇺🇸

Worcester, Massachusetts, United States

University of Louisville

🇺🇸

Louisville, Kentucky, United States

Mayo Clinic Jacksonville

🇺🇸

Jacksonville, Florida, United States

Delta Research Partners, LLC

🇺🇸

Monroe, Louisiana, United States

© Copyright 2025. All Rights Reserved by MedPath